CA1247538A
(en)
*
|
1982-05-21 |
1988-12-28 |
Mark C. Glassy |
Human-human hybridomas for solid tumors
|
US4618577A
(en)
*
|
1983-02-09 |
1986-10-21 |
The Regents Of The University Of California |
Human-human hybridoma, CLNH5
|
US4939240A
(en)
*
|
1983-03-04 |
1990-07-03 |
Health Research, Inc. |
Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
|
EP0118365B1
(en)
*
|
1983-03-04 |
1990-08-29 |
Health Research, Inc. |
Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
|
US4613576A
(en)
*
|
1983-03-09 |
1986-09-23 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies to cancer cells
|
US4693966A
(en)
*
|
1983-03-11 |
1987-09-15 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
|
GB2140030A
(en)
*
|
1983-04-08 |
1984-11-21 |
Kureha Chemical Ind Co Ltd |
Monoclonal antibody to human urinary bladder cancer
|
WO1985002411A1
(en)
*
|
1983-11-25 |
1985-06-06 |
The University Of Melbourne |
Cell line and monoclonal antibody
|
NZ210867A
(en)
*
|
1984-01-31 |
1989-01-06 |
Litton Bionetics Inc |
Tumour-specific monoclonal antibodies, production thereof and use
|
AU4070685A
(en)
*
|
1984-03-30 |
1985-10-03 |
Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibody specific for human basal cell surfaces
|
US4886745A
(en)
*
|
1984-03-30 |
1989-12-12 |
Syntex Inc. |
Monoclonal antibody specific for human basal cell surface antigen
|
JPS6133125A
(ja)
*
|
1984-07-25 |
1986-02-17 |
Morinaga & Co Ltd |
ヒト単クロ−ン性抗肺ガン細胞抗体
|
US4761377A
(en)
*
|
1984-10-15 |
1988-08-02 |
The Regents Of The University Of California |
Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
|
JPS61130300A
(ja)
*
|
1984-11-27 |
1986-06-18 |
ザ ボ−ド オブ トラステイ−ズ オブ ザ レランド スタンフオ−ド ジユニア ユニバ−シテイ |
ヒトモノクロ−ナル抗体
|
US5106746A
(en)
*
|
1985-05-22 |
1992-04-21 |
E. I. Du Pont De Nemours And Company |
Process for the in vitro immunization of human splenocytes against tumor associated antigens
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
JPH0655680B2
(ja)
*
|
1985-10-26 |
1994-07-27 |
萩原 義秀 |
悪性腫瘍用ヒトモノクロナル抗体複合剤
|
EP0222360A3
(en)
*
|
1985-11-12 |
1989-03-15 |
Biotherapeutics Inc. |
A method of producing a patient-specific cytotoxic reagent and composition
|
JPH0767388B2
(ja)
*
|
1986-01-13 |
1995-07-26 |
三菱化学株式会社 |
抗体産生細胞株の樹立方法
|
AU7165891A
(en)
*
|
1989-12-18 |
1991-07-18 |
Board Of Regents, The University Of Texas System |
Tumor-specific, cell surface-binding monoclonal antibodies
|
US5281710A
(en)
*
|
1990-08-01 |
1994-01-25 |
The Scripps Research Institute |
Dynemicin analogs: synthesis, methods of preparation and use
|
JPH04346792A
(ja)
*
|
1991-05-22 |
1992-12-02 |
Hagiwara Yoshihide |
抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするdna塩基配列
|
DE69222909T2
(de)
*
|
1991-08-16 |
1998-03-12 |
Toshiba Kawasaki Kk |
Monoklonaler Antikörper gegen ein Synaptophysin
|
DE69839517D1
(de)
|
1997-08-15 |
2008-07-03 |
Chugai Pharmaceutical Co Ltd |
Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
|
KR20020025990A
(ko)
|
1999-08-23 |
2002-04-04 |
나가야마 오사무 |
에이치엠1.24 항원의 발현 증강제
|
JP3859512B2
(ja)
|
1999-10-01 |
2006-12-20 |
中外製薬株式会社 |
血液凝固関連疾患の予防及び治療
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
CN101721362B
(zh)
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
WO2004019966A1
(ja)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質溶液製剤の安定化方法
|
EP2261230B1
(en)
|
2002-09-11 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification method
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP2228445A1
(en)
|
2003-06-18 |
2010-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose Transporter
|
JP4643450B2
(ja)
|
2003-08-08 |
2011-03-02 |
株式会社ペルセウスプロテオミクス |
癌高発現遺伝子
|
EP1707629B1
(en)
|
2003-12-03 |
2011-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Expression system using mammalian beta-actin promoter
|
US20080206229A1
(en)
|
2003-12-12 |
2008-08-28 |
Koichiro Ono |
Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
|
RU2427588C2
(ru)
|
2004-07-09 |
2011-08-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против глипикана 3
|
WO2006067847A1
(ja)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
AU2006300234B2
(en)
|
2005-10-14 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for suppressing damage to transplanted islets after islet transplantation
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
EP1967209B1
(en)
|
2005-11-25 |
2012-06-06 |
Keio University |
Therapeutic agent for prostate cancer
|
AU2007208678B2
(en)
|
2006-01-27 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for diseases involving choroidal neovascularization
|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
EP2011870A4
(en)
|
2006-04-14 |
2010-09-15 |
Medical & Biol Lab Co Ltd |
MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
|
TWI419703B
(zh)
|
2006-06-08 |
2013-12-21 |
Chugai Pharmaceutical Co Ltd |
The use of anti-NR10 antibodies with neutralizing activity against human NR10 and Cynomolgus monkey NR10
|
CA2657951A1
(en)
|
2006-06-14 |
2007-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for promoting the growth of hematopoietic stem cells
|
BRPI0714209A2
(pt)
|
2006-07-13 |
2014-06-24 |
Chugai Pharmaceutical Co Ltd |
Induzidor de morte celular
|
EP2574625B1
(en)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Remedy for renal disease
|
EP1882697B1
(en)
|
2006-07-24 |
2010-04-21 |
Institut Pasteur |
Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
|
US20100092457A1
(en)
|
2006-08-14 |
2010-04-15 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
CA2665528C
(en)
|
2006-10-12 |
2018-01-23 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-ereg antibody
|
US20100061933A1
(en)
|
2006-10-20 |
2010-03-11 |
Naoki Kimura |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
EP2123676A4
(en)
|
2007-01-05 |
2011-01-05 |
Univ Tokyo |
DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
|
US8192740B2
(en)
|
2007-02-27 |
2012-06-05 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
|
WO2009001840A1
(ja)
|
2007-06-25 |
2008-12-31 |
Forerunner Pharma Research Co., Ltd. |
ADCC活性又はCDC活性を有する抗Prominin-1抗体
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
US9096651B2
(en)
|
2007-09-26 |
2015-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in CDR
|
WO2009044774A1
(ja)
|
2007-10-02 |
2009-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
インターロイキン6受容体阻害剤を有効成分とする移植片対宿主病治療剤
|
JP5620106B2
(ja)
|
2007-10-24 |
2014-11-05 |
株式会社糖鎖工学研究所 |
増強されたエフェクター機能を有するポリペプチド
|
CN102112492B
(zh)
|
2007-11-14 |
2015-02-25 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
US9175091B2
(en)
|
2007-11-15 |
2015-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
KR101595134B1
(ko)
|
2007-12-05 |
2016-02-17 |
추가이 세이야쿠 가부시키가이샤 |
소양증 치료제
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
WO2009087978A1
(ja)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
抗cldn6抗体
|
NZ588507A
(en)
|
2008-04-11 |
2012-11-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2116261A1
(en)
|
2008-05-07 |
2009-11-11 |
Institut Pasteur |
Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
CN102256623A
(zh)
|
2008-06-05 |
2011-11-23 |
独立行政法人国立癌症研究中心 |
神经浸润抑制剂
|
WO2009154025A1
(ja)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
酸化LDL/β2GPI複合体に対する抗体及びその用途
|
KR20110099762A
(ko)
|
2008-12-26 |
2011-09-08 |
고쿠리츠다이가쿠호우진 도쿄다이가쿠 |
항lgr7항체를 사용하는 암의 진단 및 치료
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2426149A4
(en)
|
2009-05-01 |
2013-01-23 |
Univ Tokyo |
ANTI-CADHERIN ANTIBODY
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
NZ598127A
(en)
|
2009-07-31 |
2014-03-28 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
EP2535358B1
(en)
|
2010-02-10 |
2017-12-20 |
Fujifilm RI Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
WO2011105573A1
(ja)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
抗icam3抗体およびその用途
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
US9539322B2
(en)
|
2010-05-28 |
2017-01-10 |
National University Corporation Hokkaido University |
Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
|
WO2012061120A1
(en)
|
2010-10-25 |
2012-05-10 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
LT2634194T
(lt)
|
2010-10-29 |
2018-10-25 |
Perseus Proteomics Inc. |
Anti-cdh3 antikūnas su dideliu gebėjimu internalizuotis
|
EP2735315B1
(en)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Stable protein-containing preparation containing argininamide or valinamide
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
JP6291254B2
(ja)
|
2011-10-28 |
2018-03-14 |
中外製薬株式会社 |
癌幹細胞特異的分子
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
AU2012376421A1
(en)
|
2012-04-04 |
2014-11-13 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
|
US9616101B2
(en)
|
2012-07-06 |
2017-04-11 |
Kyoto Prefectural Public University Corporation |
Differentiation marker and differentiation control of eye cell
|
WO2014051022A1
(ja)
|
2012-09-27 |
2014-04-03 |
中外製薬株式会社 |
Fgfr3融合遺伝子およびそれを標的とする医薬
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
DK3087986T3
(da)
|
2013-12-27 |
2019-12-02 |
Chugai Pharmaceutical Co Ltd |
Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme
|
US20170362304A1
(en)
|
2014-08-20 |
2017-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
PL3263132T3
(pl)
|
2015-02-27 |
2024-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Kompozycja do leczenia chorób związanych z il-6
|
EP3604340A4
(en)
|
2017-03-24 |
2021-01-06 |
Zenyaku Kogyo Co., Ltd |
ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
SG11202108494YA
(en)
|
2019-02-28 |
2021-09-29 |
Juntendo Educational Found |
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
|
KR20220019670A
(ko)
|
2019-04-17 |
2022-02-17 |
고쿠리츠다이가쿠호진 히로시마다이가쿠 |
Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
|
JPWO2020250940A1
(es)
|
2019-06-11 |
2020-12-17 |
|
|
US20230149555A1
(en)
|
2020-04-06 |
2023-05-18 |
PhotoQ3 Inc. |
Medicament for killing tumor cells
|
BR112023000216A2
(pt)
|
2020-07-28 |
2023-02-07 |
Chugai Pharmaceutical Co Ltd |
Preparação de seringa pré-carregada com agulha, com proteção de agulha e incluindo anticorpo modificado
|
BR112023003511A2
(pt)
|
2020-08-27 |
2023-04-11 |
Meiji Seika Pharma Co Ltd |
Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica
|
WO2022191306A1
(ja)
|
2021-03-12 |
2022-09-15 |
中外製薬株式会社 |
重症筋無力症の治療または予防用の医薬組成物
|
EP4412583A1
(en)
|
2021-10-04 |
2024-08-14 |
Novartis AG |
Surfactant stabilizers
|
CA3239389A1
(en)
|
2021-12-01 |
2023-06-08 |
Kohei SOEDA |
Method for preparing antibody-containing formulation
|